Lynparza (olaparib) vs Phesgo (pertuzumab, trastuzumab, and hyaluronidase)
Lynparza (olaparib) vs Phesgo (pertuzumab, trastuzumab, and hyaluronidase)
Lynparza (olaparib) is a targeted therapy known as a PARP inhibitor, used primarily to treat certain types of breast, ovarian, fallopian tube, or peritoneal cancers in patients with specific genetic mutations (BRCA1 or BRCA2). Phesgo, on the other hand, is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, plus hyaluronidase, and is used to treat HER2-positive breast cancer, which is a different subset of breast cancer characterized by an overexpression of the HER2 protein. The choice between Lynparza and Phesgo would depend on the specific genetic and molecular characteristics of the cancer, as well as the patient's overall health and treatment history, making it crucial to consult with an oncologist to determine the most appropriate therapy.
Difference between Lynparza and Phesgo
Metric | Lynparza (olaparib) | Phesgo (pertuzumab, trastuzumab, and hyaluronidase) |
---|---|---|
Generic name | Olaparib | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf |
Indications | Ovarian, breast, pancreatic, and prostate cancer | Breast cancer |
Mechanism of action | Poly (ADP-ribose) polymerase (PARP) inhibitor | HER2/neu receptor antagonist and enzyme |
Brand names | Lynparza | Phesgo |
Administrative route | Oral | Subcutaneous injection |
Side effects | Anemia, nausea, fatigue, vomiting, etc. | Diarrhea, alopecia, nausea, fatigue, etc. |
Contraindications | Hypersensitivity to olaparib or any of the excipients | Hypersensitivity to active substances or excipients |
Drug class | Antineoplastic agent | Antineoplastic and immunomodulating agent |
Manufacturer | AstraZeneca and Merck & Co. (MSD) | Genentech (Roche) |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza, also known by its generic name olaparib, is a targeted therapy medication primarily used in the treatment of certain types of breast cancer. It is a PARP inhibitor that works by interfering with the DNA repair process in cancer cells, which can lead to cell death, particularly in cells that are already compromised due to a BRCA mutation. Lynparza has shown efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously received chemotherapy. Clinical trials have demonstrated a significant improvement in progression-free survival in patients treated with olaparib compared to those who received standard chemotherapy.
The effectiveness of Lynparza was highlighted in the OlympiAD trial, which was a pivotal phase III study. This trial reported that olaparib substantially delayed disease progression with a median progression-free survival of 7.0 months, compared to 4.2 months in patients who received standard therapy. Furthermore, the response rate was higher among patients treated with Lynparza, and some quality-of-life measures favored the olaparib group. These results established Lynparza as an important option for patients with BRCA-mutated metastatic breast cancer.
Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) Efficacy in Breast Cancer
Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with the enzyme hyaluronidase, and is used in the treatment of HER2-positive breast cancer. This combination allows for subcutaneous injection, which simplifies the administration of these previously intravenous-only medications. Pertuzumab and trastuzumab target the HER2 protein, which is overexpressed in certain breast cancers and promotes the growth of cancer cells. By inhibiting HER2 signaling and calling the immune system to attack the cancer cells, this combination has shown significant efficacy in treating HER2-positive breast cancer.
In clinical trials, Phesgo has demonstrated a non-inferiority in efficacy compared to the intravenous formulations of pertuzumab and trastuzumab. The pivotal study, the FeDeriCa trial, confirmed that the combination delivered through subcutaneous injection achieved comparable levels of the drugs in the blood and similar efficacy outcomes. Patients receiving Phesgo experienced a reduction in the risk of disease worsening or death, and the treatment was effective in both the neoadjuvant (before surgery) and adjuvant (after surgery) settings. The convenience of subcutaneous administration without compromising efficacy makes Phesgo an innovative treatment option for patients with HER2-positive breast cancer.
Regulatory Agency Approvals
Lynparza
Phesgo
Access Lynparza or Phesgo today
If Lynparza or Phesgo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us